Epigenetics in Heart Failure

Abstract

Heart failure is a clinical syndrome with rising global incidence and poor prognosis despite improvements in medical therapy. There is increasing research interest in epigenetic therapies for heart failure. Pathological cardiac remodelling may be driven by stress-activated cardiac signalling cascades, and emerging research has shown the involvement of epigenetic signals that regulate transcriptional changes leading to heart failure. In this review, we appraise the current evidence for the role of epigenetic modifications in heart failure. These include DNA methylation and histone modifications by methylation, acetylation, phosphorylation, ubiquitination and sumoylation, which are critical processes that establish an epigenetic pattern and translate environmental stress into genetic expression, leading to cardiac remodeling. We summarize the potential epigenetic therapies currently in development, including the limited clinical trials of epigenetic therapies in heart failure. The dynamic changes in the epigenome in the disease process require further elucidation, and so does the impact of this process on the development of therapeutics. Understanding the role of epigenetics in heart failure may pave the way for the identification of novel biomarkers and molecular targets, and facilitate the development of personalized therapies for this important condition.

Keywords: DNA methylation; epigenetic modification; heart failure; histone modifications; personalized medicine.

Figure 1

Summary of epigenetic modifications.

Figure 2

Overview of epigenetics changes in heart failure pathogenesis. HMTs, histone methyltransferases; HATs, histone acetyltransferases; CaMKIIδ, calcium/calmodulin-dependent protein kinase IIδ; RNF20, Ring Finger Protein 20; PRC1, polycomb repressive complex 1; TET, ten-eleven translocation; DNMTs, de novo methyltransferases; JMJD1C, Jumonji domain-containing 1C; TIMP, tissue inhibitor of matrix metalloproteinase; HDAC, histone deacetylases; GATA4, GATA-binding protein 4; NPPA, natriuretic peptide A; Hsp27, heat shock protein 27; MMP, matrix metalloprotease.